Salient Oncology
Updates

Oncology data is accumulating faster than ever.
So is burnout.
Staying current is essential to patient care, but finding the time is increasingly difficult.Enter CarcinoS.A physician-developed platform that uses a rigorous, multistage evidence-selection pipeline, with minimal reliance on AI, to continuously identify, score, and curate the most important new oncology research, FDA approvals, and guideline updates.Personalized to your preferences. Reviewed by a physician. Delivered to you Tuesday evening only when practice-impacting.

4:01
▋▋ 📶 ▬
C S
Carcino S
Week of Mar 30 ⌕
✓ Up to date · Last scan: 2h ago
PRACTICE IMPACTING ■■■
Tarlatamab improves OS in relapsed SCLC
NEJM · Phase III · FDA Approved
OS HR 0.60 · 13.6 vs 8.3 mo
›
Nivolumab + AVD approved in untreated cHL
FDA · SWOG S1826 · Hematology
3-yr PFS 91% vs 82%
›
Aca + venetoclax all-oral approved in CLL
FDA · AMPLIFY · First fixed-duration
Practice-changing
›
INCREMENTAL ■■ 2 updates ›
TALAPRO-2 final OS in mCRPC
The Lancet · Phase III · GU
OS HR 0.80 · 45.8 vs 37.0 mo
›
Relacorilant approved in platinum-resistant ovarian Ca
FDA · ROSELLA · Gynecologic
OS HR 0.65 · 16.0 vs 11.9 mo
›
HORIZON ■ 4 signals ›
PATINA: palbociclib in HR+/HER2+ BC
NEJM · Phase III · Breast
›
Belzutifan + lenvatinib vs cabozantinib
ASCO GU 2026 · Phase III · RCC
›
⌂ Home
🔔 Updates
👤 Profile
What you get

Every useful finding gets its own card.

Each card is assigned a tier. Only Practice-Impacting cards are sent to you as alerts, based on your preferences.A real example, annotated.

1
Journal: ASTRO / IJROBP  ·  Date: 9/28/26
2

NRG-CC009: A Phase III Trial of Stereotactic Radiosurgery vs Hippocampal-Avoidant Whole-Brain Radiotherapy for Brain Metastases From Small-Cell Lung Cancer

3

Study / regimen: Patients with SCLC and brain metastases suitable for SRS (≤4 cm each, total volume ≤30 cm³, ≥5 mm from the hippocampi).

4

Key findings: Neurocognitive failure was not significantly different with SRS vs HA-WBRT + memantine (adj. HR 0.83; P=0.39), while OS favored SRS (median 17.4 vs 8.6 mo; adj. HR 0.60; P=0.016).

5

So what (clinical implication): SRS can be considered a standard option for selected patients with SCLC brain metastases, a population historically excluded from SRS trials. The large OS difference warrants longer follow-up.

6■■■ PRACTICE-IMPACTING 78↗ Read paper
9 DISCUSSION
Radiation Oncologist · Academic Medical Center
Great to finally have level 1 evidence here. I had already moved to SRS for SCLC based on retrospective data, but this supports the change in my practice.
  1. 1
    Source & date
  2. 2
    The study, as published
    Always a real, identifiable paper
  3. 3
    Study / regimen
  4. 4
    Key findings
    Checked against the source text
  5. 5
    So what
    Clinical implication, physician-approved
  6. 6
    Tier
    Only Practice-Impacting is emailed
  7. 7
    Like
  8. 8
    Read paper
    One click to the original
  9. 9
    Discussion with colleagues
  • Always a real, identifiable paper
  • Key findings checked against the source text
  • Physician-approved "so what"
  • Only Practice-Impacting findings are emailed
How CarcinoS works for you

In an average week, hundreds of new papers become a handful of alerts.

~800 new papers scanned~20 make it through scoring2–4 practice-impacting alerts sent to you

That's over 99% less for you to sift through each week. Everything else worth knowing stays searchable on the site.

Live digest

See what CarcinoS surfaces this week

Browse the current week's curated oncology updates — no account required.

View this week's digest →
Where CarcinoS fits

Not another AI tool. Not another newsletter.

CarcinoS is

  • Proactive: finds what you didn't know to look for
  • Mostly deterministic: defined sources, the same rules and scoring every week
  • Physician adjudicated: a practicing oncologist makes the final call
  • Quiet: typically 2–4 alerts a week, not a firehose

CarcinoS isn't

  • A chatbot or AI summarizer
  • A replacement for OpenEvidence or UpToDate
  • Another daily newsletter
  • Patient-specific advice

OpenEvidence answers your clinical questions.
CarcinoS brings you the evidence that matters—without you ever having to ask.

Testimonials

What oncologists are saying.

“

Staying current in oncology is a challenge. CarcinoS allows me to focus on patient care while feeling confident I'm not missing the few updates that actually impact my patients.

Radiation Oncologist  ·  Academic Medical Center
“

The best part of CarcinoS is its focus on what is truly salient to my current practice, rather than filling the feed with random, low-value articles. The updates are concise, and the organized, searchable archive makes it easy to go back and find important developments from prior months.

Medical Oncologist  ·  Academic Cancer Center
“

CarcinoS complements tools like OpenEvidence. Rather than simply providing quick answers, CarcinoS helps physicians stay informed, engaged with new evidence, and continue learning for themselves.

Radiation Oncologist  ·  Community Cancer Center
Jeffrey Brower, MD, PhD Founded by Jeffrey Brower, MD, PhD, practicing oncologist
10+ years as an editor for oncology journals, educational resources and accrediting bodies
About the founder →
CarcinoS at work
Atezolizumab + carboplatin in ES-SCLC · NEJM · Phase III
FOLFOX vs FOLFIRI first-line mCRC · JCO · Phase III
Tarlatamab OS benefit in relapsed SCLC · NEJM ■■■
Sacituzumab govitecan in HR+ mBC · ASCO 2026
Lenvatinib + everolimus RCC subgroup · Lancet Oncol
Olaparib maintenance BRCA2+ pancreatic · NEJM
Nivolumab + AVD in untreated cHL · FDA ■■■
Cabozantinib + atezolizumab HCC phase II · JCO
Pembrolizumab neoadjuvant TNBC 3-yr OS · ASCO
Tepotinib MET exon 14 NSCLC real-world · Lung Cancer
Iniparib in TNBC: final survival data · Cancer
Aca + venetoclax all-oral CLL · FDA AMPLIFY ■■■
Selinexor + bortezomib in MM · Blood · Phase III
Ipilimumab + nivolumab MPM 5-yr OS · Lancet
Lorlatinib vs crizotinib ALK+ NSCLC update · NEJM
Durvalumab stage III NSCLC PACIFIC 5-yr · JTO
Trastuzumab deruxtecan HER2-low mBC · Breast Cancer Res
Zanubrutinib vs ibrutinib CLL · NEJM · Phase III
Regorafenib mCRC third-line survival · Ann Oncol
Enfortumab vedotin + pembro urothelial · JCO
Belantamab mafodotin MM phase II update · Blood
Tucatinib + trastuzumab HER2+ mCRC · Lancet Oncol
Mirvetuximab IMGN853 platinum-resistant OC · ASCO
Cemiplimab cSCC final OS · JCO · Phase II
Atezolizumab + carboplatin in ES-SCLC · NEJM · Phase III
FOLFOX vs FOLFIRI first-line mCRC · JCO · Phase III
Tarlatamab OS benefit in relapsed SCLC · NEJM ■■■
Sacituzumab govitecan in HR+ mBC · ASCO 2026
Lenvatinib + everolimus RCC subgroup · Lancet Oncol
Olaparib maintenance BRCA2+ pancreatic · NEJM
Nivolumab + AVD in untreated cHL · FDA ■■■
Cabozantinib + atezolizumab HCC phase II · JCO
Pembrolizumab neoadjuvant TNBC 3-yr OS · ASCO
Tepotinib MET exon 14 NSCLC real-world · Lung Cancer
Iniparib in TNBC: final survival data · Cancer
Aca + venetoclax all-oral CLL · FDA AMPLIFY ■■■
Selinexor + bortezomib in MM · Blood · Phase III
Ipilimumab + nivolumab MPM 5-yr OS · Lancet
Lorlatinib vs crizotinib ALK+ NSCLC update · NEJM
Durvalumab stage III NSCLC PACIFIC 5-yr · JTO
Trastuzumab deruxtecan HER2-low mBC · Breast Cancer Res
Zanubrutinib vs ibrutinib CLL · NEJM · Phase III
Regorafenib mCRC third-line survival · Ann Oncol
Enfortumab vedotin + pembro urothelial · JCO
Belantamab mafodotin MM phase II update · Blood
Tucatinib + trastuzumab HER2+ mCRC · Lancet Oncol
Mirvetuximab IMGN853 platinum-resistant OC · ASCO
Cemiplimab cSCC final OS · JCO · Phase II
C S
Pipeline + editor
■■■ Practice-Impacting
Tarlatamab · Nivolumab+AVD · Aca+Ven
3 studies · immediate action required
■■ Incremental
TALAPRO-2 · Relacorilant
2 updates · noteworthy evidence
■ Horizon
PATINA · Belzutifan · +3 more
5 signals · watch & monitor

Common questions

Everything you need to know before signing up.

How is CarcinoS different from OpenEvidence or ChatGPT? +

Those tools answer questions you already know to ask. CarcinoS works the other way: it monitors the literature continuously and tells you when something appears that could change your practice, before you know to look for it. Selection is done by a deterministic pipeline and a physician editor, not a prompt, and every card links to its original source.

How often will I receive updates? +

CarcinoS delivers curated weekly updates on the website covering the prior week's oncology literature. Email notifications are reserved for practice-impacting findings and will only be sent to your email when qualifying evidence emerges.

What disease sites are included? +

CarcinoS covers all major solid tumor oncology specialties including lung, breast, gastrointestinal, genitourinary, CNS, head & neck, gynecologic, melanoma, sarcoma, and hepatobiliary cancers. Coverage expands continuously.

Is any patient data involved? +

No. CarcinoS monitors the published oncology literature only. No patient records, clinical notes, or identifiable health information of any kind are ever collected or processed.

Who reviews and classifies the content? +

AI-assisted triage identifies and scores candidate papers against a structured clinical relevance framework. All tier assignments are reviewed with human editorial oversight from practicing oncologists before publication in the digest.